Merel C Broers1, Carina Bunschoten2, Daan Nieboer3, Hester F Lingsma3, Bart C Jacobs2,4. 1. Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, m.broers@erasmusmc.nl. 2. Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 3. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 4. Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract
BACKGROUND: Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence. METHOD: A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates. RESULTS: Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21-0.53; I2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58-4.39; I2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria. CONCLUSION: These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP.
BACKGROUND: Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence. METHOD: A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates. RESULTS: Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21-0.53; I2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58-4.39; I2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria. CONCLUSION: These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP.
Authors: Ivan Rocha Ferreira da Silva; Jennifer A Frontera; Ana Maria Bispo de Filippis; Osvaldo Jose Moreira do Nascimento Journal: JAMA Neurol Date: 2017-10-01 Impact factor: 18.302
Authors: E A Cats; W-L van der Pol; S Piepers; H Franssen; B C Jacobs; R M van den Berg-Vos; J B Kuks; P A van Doorn; B G van Engelen; J J Verschuuren; J H Wokke; J H Veldink; L H van den Berg Journal: Neurology Date: 2010-08-31 Impact factor: 9.910
Authors: Y A Rajabally; G Nicolas; F Piéret; P Bouche; P Y K Van den Bergh Journal: J Neurol Neurosurg Psychiatry Date: 2009-07-20 Impact factor: 10.154
Authors: B Tackenberg; J D Lünemann; A Steinbrecher; E Rothenfusser-Korber; M Sailer; W Brück; S Schock; R Zschenderlein; F Zipp; N Sommer Journal: Neurology Date: 2007-05-08 Impact factor: 9.910
Authors: Vera Bril; Christopher M Blanchette; Joshua M Noone; M Chris Runken; Deborah Gelinas; James W Russell Journal: J Diabetes Complications Date: 2016-05-10 Impact factor: 2.852
Authors: Diamantis Athanasopoulos; Jeremias Motte; Anna Lena Fisse; Thomas Grueter; Nadine Trampe; Dietrich Sturm; Martin Tegenthoff; Melissa Sgodzai; Rafael Klimas; Luis Querol; Ralf Gold; Kalliopi Pitarokoili Journal: Ann Clin Transl Neurol Date: 2020-05-20 Impact factor: 4.511